Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

3상 완료 NCT03976323

요약

The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, versus (vs) pembrolizumab plus maintenance pemetrexed for the treatment of non-squamous NSCLC. The study's 2 primary hypotheses are: 1. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent clinical review (BICR) and 2. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to overall survival (OS).

Progression-free Survival (PFS)

Up to ~31 months · Months

Overall Survival (OS)

Up to ~51 months · Months

BENITIONS에서 보기 ClinicalTrials.gov 원문 보기

같은 질환의 다른 임상

• Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given P — Merck Sharp & Dohme LLC
• Parkinson Disease and DBS: Cognitive Effects in GBA Mutation Carriers — Rutgers, The State University of New Jersey
• Evaluation of Advanced Imaging and Visualization for Clinical Deep Brain Stimulation — Duke University
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemot — Merck Sharp & Dohme LLC
• A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advan — Merck Sharp & Dohme LLC
• A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With E — Hoffmann-La Roche

전체 임상